Diurnal Group Chronocort – seeking regulatory advice

Hardman & Co Report Report DownloadsDiurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. Alkindi is being launched in key EU markets, and this was expected to be followed by Chronocort; however, headline data from its EU Phase III trial in CAH did not show superiority over standard-of-care, thereby failing to meet its primary end-point. DNL is seeking ‘Scientific Advice’ from the EMA about how to proceed, which should be available in 2Q’19, with a view to filing for market authorisation in Europe.

Strategy: DNL’s strategic goal is to create a valuable ‘Adrenal Franchise’ that can treat patients with chronic cortisol deficiency diseases from birth and for the rest of their lives. The long-term vision, once Alkindi and Chronocort are established in Europe and the US, is to expand the product offering to other endocrine conditions.

Phase III results: The full data set has now been analysed and despite not meeting its primary end-point of superiority, Chronocort was seen as efficacious and conferring many advantages over standard-of-care, such as improved androgen control in the critical morning period and lower levels of androgen over 24 hours.

EMA Scientific Advice: A briefing package for Chronocort requesting ‘Scientific Advice’ has been submitted to the EMA. It includes additional analysis from the trial and the Phase III safety extension currently running, showing the benefits of Chronocort. The meeting is expected to take place in 1Q’19, with feedback in 2Q’19.

Risks: While there is a risk with all drugs in development that they might fail clinical trials or not be approved, DNL had been considered to have unusually low risk, as its products are formulations of well-established drugs. Following Alkindi’s approval in Europe, the Chronocort outcome was unexpected.

Investment summary: Alkindi, a cortisol replacement therapy designed for babies and children, is DNL’s first product on the market. It had been expected to be followed by Chronocort for adults – a much larger market. The fall in the share price following this unpredictable outcome looks overdone, but the price is likely to languish in the short term until there is clarity from the regulators about how to move Chronocort forward (in 2Q’19).

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Diurnal Group: All set for three pivotal trials

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its drugs target conditions where medical need is currently unmet, with the aim of becoming a global endocrine leader.

    Hardman & Co

    Diurnal Group: And then there were three

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group: Closely watching the regulators

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group Flow of regulatory approvals

    Diurnal Group plc (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its products are targeting rare conditions where medical need is currently unmet, with the long-term aim of building an

    Hardman & Co

    Diurnal Group … and more to come (news flow)

    Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building

    Hardman & Co

    Diurnal Group Plc Successful DITEST Phase I trial outcome

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful

    Hardman & Co

    Diurnal Group Approaching a number of near-term milestones

    Diurnal (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Plc Clarity for Chronocort regulatory pathway

    Diurnal Group Plc (LON: DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of

    Hardman & Co

    Diurnal Group Unexpected Phase III trial outcome

    Diurnal Group (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term

    Hardman & Co

    Diurnal Group Alkindi®: On route to Europe

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building

    Hardman & Co

    Diurnal Group Plc Ready to press the button

    Diurnal Group Plc (LON:DNL) is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building